COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines

Table 5

Variables and outcomes among non-COVID-19 patients.

	ICU survivors (n = 45)	ICU nonsurvivors (n = 15)	value (two-tailed)
Demographics
Age (years)	68 (±15)	57 (±14)	0.015
Gender (% of males)	60%	80%	0.218
SAPS-3	47.8 (±12.8)	58.7 (±20.1)	0.066
Comorbidities
Neurologic			0.026
Yes	13 (28.9%)	0
No	32 (71.1%)	15 (100%)
Cardiovascular			0.250
Yes	39 (86.7%)	11 (73.3%)
No	6 (13.3%)	4 (26.7%)
Pulmonary			0.242
Yes	16 (35.6%)	8 (53.3%)
No	29 (64.4%)	7 (46.7%)
Renal			0.375
Yes	22 (48.9%)	5 (33.3%)
No	23 (51.1%)	10 (66.7%)
Endocrine			0.552
Yes	20 (44.4%)	5 (33.3%)
No	25 (55.6%)	10 (66.7%)
Autoimmune			1.000
Yes	5 (11.1%)	2 (13.3%)
No	40 (88.9%)	13 (86.7%)
Malignancy			0.208
Yes	5 (11.1%)	4 (26.7%)
No	40 (88.9%)	11 (73.3%)
Laboratories on ICU admission
Hemoglobin (g/L)	118 (±31)	126 (±30)	0.358
WBC count (×10^3/µL)	13.6 (±10)	11.3 (±7)	0.328
Platelets (×10^9/L)	226 (±87)	274 (±157)	0.275
PF ratio	273 (±142)	203 (±133)	0.154
Lactate (mmoL/L)	2.9 (±2.2)	2.8 (±1.6)	0.948
Treatment strategy
Hydroxychloroquine			0.036
Yes	4 (8.9%)	5 (33.3%)
No	41 (91.1%)	10 (66.7%)
Tocilizumab			0.059
Yes	0	2 (13.3%)
No	45 (100%)	13 (86.7%)
Lopinavir/ritonavir			0.250
Yes	0	1 (6.7%)
No	45 (100%)	14 (93.3%)
CRRT			0.250
Yes	6 (13.3%)	4 (26.7%)
No	39 (86.7%)	11 (73.3%)
NMBA			0.059
Yes	0	2 (13.3%)
No	45 (100%)	13 (86.7%)
Prone positioning			0.151
Yes	1 (2.2%)	2 (13.3%)
No	44 (97.8%)	13 (86.7%)
IVIG			—
Yes	0	0
No	45 (100%)	15 (100%)
HA-330			—
Yes	0	0
No	45 (100%)	15 (100%)
Intubation			0.001
Yes	20 (44.4%)	14 (93.3%)
No	25 (55.6%)	1 (6.7%)
Others
Number of days intubated	10 (±7)	5 (±5)	0.036